German Non-Substitution List Will Slow Price Erosion For Older Drugs
This article was originally published in The Pink Sheet Daily
Germany’s senior reimbursement body has published the country’s first list of non-substitutable drugs, which, though sparse for now, could put a stop to price erosion for older products.
You may also be interested in...
Proposals designed to expand patient choice over which medicines they take risk undermining Germany's discount contract system, thereby increasing drug costs, the country's largest health insurer, AOK, says.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.